Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): July 8, 2002.

                                  BioTime, Inc.
             (Exact name of registrant as specified in its charter)

                            (Commission File Number)

             California                               94-3127919
    (State or other jurisdiction                     (IRS Employer
          of incorporation)                        Identification No.)

                                935 Pardee Street
                           Berkeley, California 94710
                    (Address of principal executive offices)

                                 (510) 845-9535
              (Registrant's telephone number, including area code)

         Statements  made in this  Report  that  are not  historical  facts  may
constitute   forward-looking   statements   that  are   subject   to  risks  and
uncertainties  that could cause actual results to differ  materially  from those
discussed.  Such risks and  uncertainties  include  but are not limited to those
discussed in this report and in BioTime's  Annual Report on Form 10-K filed with
the Securities and Exchange Commission.  Words such as "expects," "may," "will,"
"anticipates," "intends," "plans," "believes," "seeks," "estimates," and similar
expressions identify forward-looking statements.

Item 5.  Other Events.

         The Health  Products  and Food  Branch,  Health  Canada,  has  approved
Hextend(R) for sale in Canada. Hextend is BioTime's proprietary hetastarch-based
plasma volume expander with lactate,  multiple  electrolytes,  and physiological
amounts of glucose.  Hextend will be marketed in Canada by Abbott  Laboratories,
Limited, Canada, an affiliate of Abbott International.


         Pursuant to the  requirements  of the Securities  Exchange Act of 1934,
the  registrant  has duly  caused  this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                            BIOTIME, INC.

Date:  July 9, 2002                  By     /s/ Paul Segall
                                            Paul E. Segall
                                            Chairman and Chief Executive Officer